Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $41.00.

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st.

Insider Buying and Selling at Enliven Therapeutics

In other news, COO Anish Patel sold 48,300 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This trade represents a 18.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the completion of the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 233,843 shares of company stock valued at $6,145,489. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELVN. Commodore Capital LP boosted its position in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after purchasing an additional 418,673 shares during the period. Vanguard Group Inc. boosted its holdings in Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares in the last quarter. Finally, State Street Corp grew its position in Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after buying an additional 87,725 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Down 0.5%

ELVN opened at $26.02 on Friday. The business has a 50 day moving average price of $22.84 and a two-hundred day moving average price of $21.16. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.22. The company has a market cap of $1.54 billion, a PE ratio of -14.14 and a beta of 0.34.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.